Living with lung cancer often means spending more time in waiting rooms than in the moments that matter. But that could ...

At the recent CURE Educated Patient® Lung Cancer Summit, held in tandem with the 2025 PER® New York Lung Cancer Symposium, Dr ...

Cellular therapies, including TIL, TCR, and CAR-T, are transforming lung cancer care by utilizing personalized immune cells ...

Near-term applications include combinations with kinase inhibitors (KIs)that achieve enhanced concentration at target sites and synergistic delivery of multiple KIs to the same location HOUSTON, TX / ...

When Sydney Barned was first diagnosed with stage 4 lung cancer, she was just 33 years old — a young medical intern focused ...

New NSCLC guideline updates outline expanded perioperative immunotherapy, adjuvant targeted therapy, and consolidation ...

Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.

Each year, about 209,000 Americans are told they have lung cancer, and about 132,000 people die from the disease, according ...

Jefferies London Healthcare Conference 2025 November 18, 2025 10:30 AM ESTCompany ParticipantsDave Gancarz - Chief ...

Libtayo plus chemotherapy is potentially more cost-effective than Keytruda plus chemotherapy for advanced NSCLC, offering lower costs and higher QALYs. The study's model, based on clinical trial data, ...

Michael's fought through relapse, endured a leg amputation, and conquered physical therapy while still cracking jokes with ...